Cargando…

SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System

The novel, ring-shaped, contraceptive vaginal system (CVS; Annovera™), contains 103 mg of SA and 17.4 mg of EE, and delivers a mean dose of SA 0.15/EE 0.013 mg/day. The CVS was designed to last thirteen cycles in a 21 day-in/7 day-out regimen. Objectives of these analyses were to determine the amoun...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, James H, Archer, David F, Simon, James A, Kaunitz, Andrew M, Plagianos, Marlena, Bernick, Brian, Mirkin, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209220/
http://dx.doi.org/10.1210/jendso/bvaa046.665
_version_ 1783531024394747904
author Liu, James H
Archer, David F
Simon, James A
Kaunitz, Andrew M
Plagianos, Marlena
Bernick, Brian
Mirkin, Sebastian
author_facet Liu, James H
Archer, David F
Simon, James A
Kaunitz, Andrew M
Plagianos, Marlena
Bernick, Brian
Mirkin, Sebastian
author_sort Liu, James H
collection PubMed
description The novel, ring-shaped, contraceptive vaginal system (CVS; Annovera™), contains 103 mg of SA and 17.4 mg of EE, and delivers a mean dose of SA 0.15/EE 0.013 mg/day. The CVS was designed to last thirteen cycles in a 21 day-in/7 day-out regimen. Objectives of these analyses were to determine the amount of SA/EE remaining in the CVS after 13 cycles of use and to estimate the SA level in serum after 1 year of continuous use. Residual SA/EE levels from CVS used by women (n=18) for 13 cycles of 21/7 regimen in a phase 3 clinical trial were further analyzed in vitro. Hypothetical SA level in serum after 1 year of continuous use was estimated using data from 39 women who participated in a 13-cycle pharmacokinetic study of the 21/7 CVS regimen. The serum data were used to construct a statistical model for the change in serum SA concentrations from cycle 1 to cycle 13. The data from each individual subject was modeled to estimate the serum SA level based on days of use. Each subject’s model was then used to estimate the serum SA level after 364 days of continuous CVS use. The average of all 364-day values from valid models was then calculated. After 13 cycles of a 21/7 regimen, the amount of SA/EE remaining in the CVS was 61.7 mg/14.0 mg (60%/80% of the original SA/EE load), which established the release of 0.15 mg SA and 0.013 mg EE per day for a total of 273 days. The model predicted that the mean serum SA level after 364 days of continuous use was 71 pmol/L with a lower limit of the 90% CI of 52 pmol/L. A high percentage of SA/EE remained in the CVS after 13 cycles of use. Serum SA levels predicted by the model following 1 year of continuous use were similar to those previously observed (mean 73 pmol/L) at 1 year in a SA silicone implant trial in which there were no reported pregnancies at 1 year (Sivin et al, Contraception. 2004;69:137-144). No pregnancy or PK data with continuous use of the CVS is available at this time. Further study on the continuous use of the CVS is warranted.
format Online
Article
Text
id pubmed-7209220
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72092202020-05-13 SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System Liu, James H Archer, David F Simon, James A Kaunitz, Andrew M Plagianos, Marlena Bernick, Brian Mirkin, Sebastian J Endocr Soc Reproductive Endocrinology The novel, ring-shaped, contraceptive vaginal system (CVS; Annovera™), contains 103 mg of SA and 17.4 mg of EE, and delivers a mean dose of SA 0.15/EE 0.013 mg/day. The CVS was designed to last thirteen cycles in a 21 day-in/7 day-out regimen. Objectives of these analyses were to determine the amount of SA/EE remaining in the CVS after 13 cycles of use and to estimate the SA level in serum after 1 year of continuous use. Residual SA/EE levels from CVS used by women (n=18) for 13 cycles of 21/7 regimen in a phase 3 clinical trial were further analyzed in vitro. Hypothetical SA level in serum after 1 year of continuous use was estimated using data from 39 women who participated in a 13-cycle pharmacokinetic study of the 21/7 CVS regimen. The serum data were used to construct a statistical model for the change in serum SA concentrations from cycle 1 to cycle 13. The data from each individual subject was modeled to estimate the serum SA level based on days of use. Each subject’s model was then used to estimate the serum SA level after 364 days of continuous CVS use. The average of all 364-day values from valid models was then calculated. After 13 cycles of a 21/7 regimen, the amount of SA/EE remaining in the CVS was 61.7 mg/14.0 mg (60%/80% of the original SA/EE load), which established the release of 0.15 mg SA and 0.013 mg EE per day for a total of 273 days. The model predicted that the mean serum SA level after 364 days of continuous use was 71 pmol/L with a lower limit of the 90% CI of 52 pmol/L. A high percentage of SA/EE remained in the CVS after 13 cycles of use. Serum SA levels predicted by the model following 1 year of continuous use were similar to those previously observed (mean 73 pmol/L) at 1 year in a SA silicone implant trial in which there were no reported pregnancies at 1 year (Sivin et al, Contraception. 2004;69:137-144). No pregnancy or PK data with continuous use of the CVS is available at this time. Further study on the continuous use of the CVS is warranted. Oxford University Press 2020-05-08 /pmc/articles/PMC7209220/ http://dx.doi.org/10.1210/jendso/bvaa046.665 Text en © Endocrine Society 2020. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Reproductive Endocrinology
Liu, James H
Archer, David F
Simon, James A
Kaunitz, Andrew M
Plagianos, Marlena
Bernick, Brian
Mirkin, Sebastian
SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
title SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
title_full SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
title_fullStr SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
title_full_unstemmed SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
title_short SAT-013 Segesterone Acetate (SA) Serum Levels with a Statistical Model of Continued Use of the SA/Ethinyl Estradiol (EE) Contraceptive Vaginal System
title_sort sat-013 segesterone acetate (sa) serum levels with a statistical model of continued use of the sa/ethinyl estradiol (ee) contraceptive vaginal system
topic Reproductive Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209220/
http://dx.doi.org/10.1210/jendso/bvaa046.665
work_keys_str_mv AT liujamesh sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem
AT archerdavidf sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem
AT simonjamesa sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem
AT kaunitzandrewm sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem
AT plagianosmarlena sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem
AT bernickbrian sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem
AT mirkinsebastian sat013segesteroneacetatesaserumlevelswithastatisticalmodelofcontinueduseofthesaethinylestradioleecontraceptivevaginalsystem